Nitrosamine Impurity Confirmatory Testing by MAHs
According to the CMDh practical guidance for Marketing Authorization Holders (MAHs) of nationally authorized products, the evaluation of nitrosamine impurity or cross-contamination in a marketed product is a critical criterion. Nitrosamines are proven to be carcinogenic and can affect the overall output of the formulated product.
Considering the severity, the Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) issued the following first three (03) steps a manufacturer must follow to mitigate the amount of impurity in the final drug product.